|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.66 USD | -1.76% |
|
+6.64% | +10.69% |
| Capitalization | 4.6B 3.94B 3.66B 3.42B 6.38B 415B 6.85B 42.22B 16.59B 198B 17.26B 16.9B 728B | P/E ratio 2025 * |
51.9x | P/E ratio 2026 * | 48.9x |
|---|---|---|---|---|---|
| Enterprise value | 4.67B 4B 3.72B 3.47B 6.48B 421B 6.95B 42.84B 16.84B 201B 17.51B 17.15B 738B | EV / Sales 2025 * |
7.77x | EV / Sales 2026 * | 6.31x |
| Free-Float |
96.82% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: TransMedics Group, Inc.
| 1 day | -1.76% | ||
| 1 week | +6.64% | ||
| Current month | +10.69% | ||
| 1 month | +6.21% | ||
| 3 months | +25.51% | ||
| 6 months | +19.74% | ||
| Current year | +10.69% |
| 1 week | 131 | 141.89 | |
| 1 month | 119.29 | 141.89 | |
| Current year | 120.17 | 141.89 | |
| 1 year | 55 | 156 | |
| 3 years | 36.42 | 177.37 | |
| 5 years | 10 | 177.37 | |
| 10 years | 10 | 177.37 |
| Manager | Title | Age | Since |
|---|---|---|---|
Waleed Hassanein
CEO | Chief Executive Officer | 57 | 1998-07-31 |
| Director of Finance/CFO | 55 | 2024-12-01 | |
Nick Corcoran
COO | Chief Operating Officer | 43 | 2023-02-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Waleed Hassanein
BRD | Director/Board Member | 57 | 1998-07-31 |
James Tobin
CHM | Chairman | 81 | 2010-12-31 |
Edward Basile
BRD | Director/Board Member | 78 | 2016-01-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.76% | +6.64% | +95.70% | +125.86% | 4.6B | ||
| -0.55% | +0.70% | +13.49% | +5.83% | 231B | ||
| -2.30% | +1.12% | +4.62% | +122.91% | 203B | ||
| +0.26% | +1.55% | +1.67% | -12.23% | 169B | ||
| -1.97% | +0.25% | +0.89% | +104.92% | 142B | ||
| +0.99% | +4.61% | -7.43% | -4.22% | 61.2B | ||
| -2.49% | -1.38% | +13.06% | +6.77% | 48.17B | ||
| -0.36% | +3.54% | +7.65% | -5.43% | 41.95B | ||
| -0.44% | +2.19% | +2.52% | +32.37% | 39.58B | ||
| +2.13% | +5.09% | +10.27% | +20.49% | 37.56B | ||
| Average | -0.97% | +2.43% | +14.24% | +39.73% | 97.81B | |
| Weighted average by Cap. | -1.02% | +1.39% | +6.02% | +42.53% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 601M 515M 478M 446M 834M 54.16B 894M 5.51B 2.17B 25.91B 2.25B 2.21B 95B | 725M 621M 577M 538M 1.01B 65.35B 1.08B 6.65B 2.61B 31.26B 2.72B 2.66B 115B |
| Net income | 101M 86.41M 80.36M 74.92M 140M 9.1B 150M 926M 364M 4.35B 378M 371M 15.95B | 109M 93.18M 86.65M 80.79M 151M 9.81B 162M 998M 392M 4.69B 408M 400M 17.2B |
| Net Debt | 67.83M 58.09M 54.02M 50.36M 94.1M 6.11B 101M 622M 245M 2.92B 254M 249M 10.72B | -26.7M -22.86M -21.26M -19.82M -37.04M -2.41B -39.72M -245M -96.27M -1.15B -100M -98.07M -4.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-12 | 134.66 $ | -1.76% | 580,841 |
| 26-01-09 | 137.07 $ | -0.36% | 364,281 |
| 26-01-08 | 137.57 $ | +0.22% | 692,047 |
| 26-01-07 | 137.27 $ | +3.47% | 732,998 |
| 26-01-06 | 132.67 $ | +5.06% | 692,887 |
Delayed Quote Nasdaq, January 12, 2026 at 04:00 pm EST
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TMDX Stock
Select your edition
All financial news and data tailored to specific country editions
















